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Abstract
Introduction: The purpose of this work was to study the prognostic influence in breast cancer of thioredoxin 
reductase 1 (TXNRD1) and thioredoxin interacting protein (TXNIP), key players in oxidative stress control that are 
currently evaluated as possible therapeutic targets.
Methods: Analysis of the association of TXNRD1 and TXNIP RNA expression with the metastasis-free interval (MFI) was 
performed in 788 patients with node-negative breast cancer, consisting of three individual cohorts (Mainz, Rotterdam 
and Transbig). Correlation with metagenes and conventional clinical parameters (age, pT stage, grading, hormone and 
ERBB2 status) was explored. MCF-7 cells with a doxycycline-inducible expression of an oncogenic ERBB2 were used to 
investigate the influence of ERBB2 on TXNRD1 and TXNIP transcription.
Results: TXNRD1 was associated with worse MFI in the combined cohort (hazard ratio = 1.955; P < 0.001) as well as in 
all three individual cohorts. In contrast, TXNIP was associated with better prognosis (hazard ratio = 0.642; P < 0.001) and 
similar results were obtained in all three subcohorts. Interestingly, patients with ERBB2-status-positive tumors 
expressed higher levels of TXNRD1. Induction of ERBB2 in MCF-7 cells caused not only an immediate increase in 
TXNRD1 but also a strong decrease in TXNIP. A subsequent upregulation of TXNIP as cells undergo senescence was 
accompanied by a strong increase in levels of reactive oxygen species.
Conclusions: TXNRD1 and TXNIP are associated with prognosis in breast cancer, and ERBB2 seems to be one of the 
factors shifting balances of both factors of the redox control system in a prognostic unfavorable manner.
Introduction
Control mechanisms of reactive oxygen species (ROS)
play a crucial role in tumor development. Transformed
cells are known to generate more ROS than normal cells
[1,2]. Importantly, ROS not only contribute to tumor pro-
gression by amplifying genomic instability but trans-
formed cells use ROS signals to drive proliferation [1].
Conversely, ROS addiction may render tumor cells more
vulnerable to apoptosis or senescence [3,4] because they
depend on constantly increased basal levels of ROS, and
an additional increase may exceed toxic thresholds.
Thioredoxin reductase 1 (TXNRD1) and thioredoxin
interacting protein (TXNIP; also called thioredoxin bind-
ing protein 2 or vitamin D3-upregulated protein 1) [5] are
key players in oxidative stress control.
TXNRD1 reduces and activates thioredoxin, an oxi-
doreductase containing a dithiol-disulfide active site,
which in turn reduces oxidized cysteine residues on cellu-
lar proteins. Importantly, a reducing environment medi-
ated by thioredoxin is required for effective DNA binding
of redox-sensitive transcription factors, including p53
and NF-κB [6,7]. Thioredoxin binds ROS before they can
harm cells and thus protects cells against oxidative stress.
In addition to its critical role in the regulation of cellular
redox homeostasis, thioredoxin has multiple actions in
the cell - such as activation of ribonucleotide reductase,
inhibition of apoptosis signal regulating kinase 1 and
induction of hypoxia inducible factor 1 (HIF-1) and vas-
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Page 2 of 15cular endothelial growth factor (VEGF) - which contrib-
ute to many hallmarks of cancer, such as increased
proliferation, inhibited apoptosis and angiogenesis [8].
In contrast to TXNRD1, which supports thioredoxin
function, TXNIP binds to and inhibits the reduced form
of thioredoxin [9-11], blocking its activity as well as its
interaction with other factors, including apoptosis signal
regulating kinase 1. TXNIP therefore functions as a
proapoptotic protein [12]. As for thioredoxin, multifunc-
tional roles of TXNIP are known [13,14] that point out
the crucial role of TXNIP as a link between pathways of
redox regulation, antioxidant defense, energy metabolism
and cell growth and survival [15,16]. A summary of the
roles of these key players of the thioredoxin system is pro-
vided in Figure 1.
The thioredoxin redox system has been suggested
recently as a therapeutic target for cancer therapy [17,18],
based on the observation that thioredoxin is overex-
pressed in many aggressive tumors and that siRNA-medi-
ated knockdown of TXNRD1 decreased tumor
progression and metastasis in mice [19]. Several inhibi-
tors of the thioredoxin pathway have been shown to have
antitumor activity in mice bearing breast, colon and renal
xenografts [20-22]. In addition, high thioredoxin expres-
sion in prechemotherapy tumor samples has been
reported to be associated with resistance to docetaxel in
primary breast cancer [23,24].
Despite the ongoing evaluation of the thioredoxin sys-
tem as a therapeutic target and the central role of
TXNRD1 and TXNIP in oxidative stress control, little is
known about their prognostic relevance. Increased
Figure 1 Scheme of cellular functions of the cytoplasmic thioredoxin system. Thioredoxin reductase 1 (TXNRD1) reduces thioredoxin 1 (TXN), 
which in turn reduces oxidized cysteins in cellular proteins and scavenges peroxides by peroxiredoxins (PRDX), thus protecting cells against oxidative 
stress. TXN stimulates ribonucleotide reductase (RR) activity and supports DNA synthesis. TXN stimulates the transcriptional activity of nuclear factor 
κB (NF-κB), activator protein 1 (Fos/Jun) (AP-1) and specificity protein 1 (SP-1), and elevates hypoxia inducible factor 1α (HIF-1α) protein levels, which 
in turn influence vascular endothelial growth factor (VEGF). TXN also binds to and inhibits the pro-apoptotic proteins apoptosis signal regulating ki-
nase 1 (ASK-1) and phosphatase and tensin homolog (PTEN). All these events promote cell growth, inhibit apoptosis and increase angiogenesis in 
tumors, as reviewed elsewhere [8]. Thioredoxin interacting protein (TXNIP) binds and inhibits reduced TXN. TXNIP also interacts with several transcrip-
tional co-repressors, such as promyelocytic leukemia zinc-finger (PLZF), Fanconi anemia zinc-finger (FAZF) and histone deacetylase 1 (HDAC1), and 
inhibits transcription of cyclin A2, leading to reduced cell growth. TXNIP increases p16 and p27KIP1 protein levels, leading to cell cycle arrest. TXNIP 
also associates with the von Hippel-Landau protein (pVHL), enhancing the interaction between pVHL and HIF1α to promote nuclear export and deg-
radation of HIF1α. The roles of TXNIP in the immune system and in human metabolism are not yet fully understood. For reviews, see [13,14]. CDK, 
cycline dependent kinase; FA, fatty acid; ROS, reactive oxygen species.
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Page 3 of 15expression of thioredoxin in human colorectal cancer is
associated with decreased patient survival [25], whereas
absence of thioredoxin expression in nonsmall-cell lung
carcinoma is associated with a better outcome [26].
Decreased TXNIP expression in patients with diffuse
large B-cell lymphoma has been shown to correlate with a
poor prognosis [27]. To our knowledge, however,
TXNRD1 expression and TXNIP expression have not yet
been analyzed in relation to prognosis in breast cancer. In
the present study we observed that high expression of
TXNRD1 and low expression of TXNIP are associated
with worse prognosis in breast cancer. Since both higher
TXNRD1 expression and lower TXNIP expression were
observed in ERBB2-status-positive tumors, we analyzed
whether ERBB2 can influence these factors using a MCF-
7 cell line that allows conditional expression of an onco-
genic version of ERBB2.
Materials and methods
Cultivation of MCF-7/NeuT cells and analysis of RNA 
expression patterns
The MCF-7 breast carcinoma cell line was obtained from
the American Type Culture Collection (LGC Standards
GmbH, Wesel, Germany), cultured at 37°C in a humidi-
fied 5% CO2 air atmosphere, and transfected with pIN-
SpBI-NeuT/EGFP and pcDNA3Neo/rtTA2 as described
elsewhere [3]. Expression of NeuT, an oncogenic version
of ERBB2, was induced by doxycycline (obtained as the
hydrochloride salt from Sigma, Munich, Germany) at a
final concentration of 1 μg/ml in all experiments. MCF-7/
NeuT cells were exposed to doxycycline for periods of 0,
6, 12 and 24 hours as well as 3 and 14 days. Three inde-
pendent repeat experiments were performed. Between
each repeat experiment, the MCF-7/NeuT cells were cul-
tivated for at least two passages. Cells were harvested
using TRItidy G-Reagent (AppliChem GmbH, Darm-
stadt, Germany) and RNA was isolated subsequently
according to the manufacturer's protocols and stored at -
80°C.
Before microarray analysis, RNA integrity and concen-
tration were examined using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA) with the
RNA 6000 LabChip Kit (Agilent Technologies) according
to the manufacturer's instructions. Microarray analysis
was conducted at the microarray core facility of the Inter-
disziplinäres Zentrum für klinische Forschung (Faculty of
Medicine, University of Leipzig, Germany). To create
cDNA, the High Capacity cDNA Reverse Transcription
Kit was used (Applied Biosystems, Darmstadt, Germany).
The TaqMan technique was used for further gene expres-
sion analysis by quantitative real-time PCR and confir-
mation of microarray data. Ubiquitin C was chosen as the
reference gene and the untreated cells were taken as the
controls. The expression assays used were
Hs00824723_m1 (ubiquitin C), Hs00197750_m1 (TXNIP)
and Hs00917067_m1 (TXNRD1) (Applied Biosystems).
The PCR conditions followed the standard specifications
recommended by Applied Biosystems. For calculations of
relative gene expression, we used the 2-ΔΔCt method as
described by Schug and colleagues [28].
Immunoblotting
Immunoblot analysis was performed as described else-
where [3,29]. The Neu antibody (sc-284; Santa Cruz Bio-
technology, Heidelberg, Germany) and the p44/42
mitogen-activated protein kinase antibody (#9102; Cell
Signaling, Boston, MA, USA) were diluted at 1:1,000 and
were incubated for 2 hours at room temperature. The
phospho-p44/p42 mitogen-activated protein kinase
Tyr202/Thr204 antibody (#9101; Cell Signaling) and the
phospho-Akt Ser473 (#9271; Cell Signaling) were diluted
at 1:1,000 and incubated overnight at 4°C. The phospho-
p38 mitogen-activated protein kinase Thr180/Tyr182
(3D7) (#9215; Cell Signaling) was diluted at 1:500 and
incubated overnight at 4°C. The Txnip (Vdup1) (sc-
166234; Santa Cruz) antibody was diluted 1:250 and the
Txnrd1 antibody (ab 16840; Abcam, Cambridge, UK) was
diluted 1:1,000. Both antibodies were applied overnight at
4°C. The β-actin antibody (clone AC-74; Sigma Aldrich,
Munich, Germany) was diluted 1:5,000 and was incu-
bated for 30 minutes at room temperature. Horseradish
peroxidase-conjugated secondary antibodies were
obtained from Cell Signaling (anti-rabbit-HRP, #7074) or
from Sigma (anti-mouse-HRP, A9044) and were diluted
1:10,000 in 5% bovine serum albumin/Tris-bufffered
saline Tween 20. Protein signals were detected by
enhanced chemiluminiscence (PerkinElmer LAS, Rod-
gau-Jügesheim, Germany).
Detection of malondialdehyde as a thiobarbituric acid or 
an N-methyl-2-phenylindole complex
Malondialdehyde (MDA) is a major degradation product
of lipid hydroperoxides and is widely used as a marker of
lipid peroxidation. To estimate the content of MDA in a
sample we performed two analytical methods.
First, we measured thiobarbituric acid reactive sub-
stances via high-performance liquid chromatography
according to the procedure described [30]. Aqueous
trichloroacetic acid in the presence of hexane and buty-
lated hydroxytoluene was used to homogenize the sam-
ple. Within this reaction a complex of MDA and 1,3-
diethyl-2-thiobarbituric acid (DETBA) is formed. The
chromophore of the MDA-DETBA adduct was then
chromatographed on a high-performance liquid chroma-
tography column and quantified by fluorescence emis-
sion at 553 nm with an excitation at 532 nm.
Second, we used a spectrophotometric assay based on a
reaction of MDA with N-methyl-2-phenylindole
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USA). One molecule of MDA reacts with two molecules
of N-methyl-2-phenylindole. The resulting stable carbo-
cyanine dye shows a maximum absorption at 586 nm and
was detected spectrophotometrically. For MDA estima-
tion, eight measurements of three independent experi-
ments were performed.
Patient characteristics, tissue specimens and gene array 
analysis
Three recently described cohorts of 788 node-negative
breast cancer patients who did not receive chemotherapy
were analyzed [31]. The combined cohort consisted of
three individual cohorts: the Mainz cohort (n = 200), the
Rotterdam cohort (n = 286) and the Transbig cohort (n =
302).
The Mainz study cohort consists of 200 lymph node-
negative breast cancer patients treated at the Department
of Obstetrics and Gynecology of the Johannes Gutenberg
University Mainz between 1988 and 1998 [31]. Patients of
the Mainz cohort were all treated with surgery and did
not receive any systemic therapy in the adjuvant setting.
The established prognostic factors (histological grade,
tumor size, age at diagnosis, and steroid receptor status)
were collected from the original pathology reports of the
gynecologic pathology division within our department.
Patients' characteristics have been published by Schmidt
and colleagues [31] and are described in Additional file 1.
For all tumors, samples were snap-frozen and stored at -
80°C. Gene expression profiling of the patients' RNA was
performed using the Affymetrix HG-U133A array and
the GeneChip System as described [31]. These data have
been deposited in the National Center for Biotechnology
Information Gene Expression Omnibus (GEO) and are
accessible [GEO:GSE11121].
Results obtained from the Mainz cohort were validated
in two previously published microarray datasets. Two
breast cancer Affymetrix HG-U133A microarray datasets
including patient outcome information were downloaded
from the National Center for Biotechnology Information
GEO data repository. The first dataset, the Rotterdam
cohort [32], represents 180 lymph node-negative relapse-
free patients [GEO:GSE2034] and 106 lymph node-nega-
tive patients that developed a distant metastasis. None of
these patients had received systemic neoadjuvant or adju-
vant therapy (Rotterdam cohort). The original data were
recalculated to a mean target intensity (TGT) of 500. The
second dataset, the Transbig cohort, consists of 302 sam-
ples from breast cancer patients that remained untreated
in the adjuvant setting after surgery [33,34]. GEO sample
record numbers of samples [GEO:GSE6532,
GEO:GSE7390] used for analysis are listed in the supple-
mentary tables previously published by Schmidt and col-
leagues [31]. Raw .cel file data were processed by MAS 5.0
using a TGT of 500.
Ethical approval for the analysis of RNA levels was




Univariate and multivariate Cox models were applied to
analyze a possible association of TXNRD1 and TXNIP
RNA expression (log2 transformed) with prognosis. Dis-
ease-free survival was computed from the date of diagno-
sis to the date of local recurrence of disease, or distant
metastasis, or cancer of the contralateral breast, or death
from cancer. The metastasis-free survival interval (MFI)
was computed from the date of diagnosis to the date of
diagnosis of distant metastasis. Patients who died of an
unrelated cause were censored at the date of death. Sur-
vival times were compared using Kaplan-Meier plots and
the log-rank test. Since the frequency distributions of
TXNRD1 and TXNIP did not perfectly match a normal
distribution (Additional file 2) we used nonparametric
tests for comparison of groups, such as the Mann-Whit-
ney test for unpaired data.
Dichotomization was performed as described by
Schmidt and colleagues [35,36]. Briefly, the cut-off points
differentiating between high and low expression were
identified in the combined cohort of patients from
Mainz, from Rotterdam and from the Transbig group
(Additional file 3). Similar bimodal distributions and cut-
off points were observed in each individual cohort (Addi-
tional file 4). Cut-off points of 10 (estrogen receptor), 12.6
(ERBB2) and 4.9 (progesterone receptor) could therefore
be used for all cohorts. Dichotomization was performed
using these cut-off points to generate the following
dichotomous variables: ERBB2 status, estrogen receptor
status, progesterone receptor status and hormone recep-
tor status (which is positive when only one of both estro-
gen or progesteron receptor status is positive).
Concerning histological grading, the patients were
dichotomized into grade III versus grade I and grade II,
and pT stage into pT2 and pT3 (> 2 cm) versus pT1 (≤ 2
cm) (for patient characteristics see Additional file 1).
Correlations were analyzed using the Spearman corre-
lation test. All P values are two-sided. As no correction
for multiple testing was performed, the values should be
regarded as descriptive measures. All analyses were per-
formed using SPSS17.0 (SPSS Inc., Chicago, IL, USA).
Results
TXNDR1 and TXNIP are associated with prognosis in breast 
cancer
To study a possible association with the MFI, we analyzed
our cohort (Mainz cohort) of patients and validated the
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and Transbig cohorts). All patients were node-negative
and did not receive chemotherapy. In the Mainz cohort,
high TXNRD1 RNA expression was associated with a
higher hazard ratio (HR = 1.920; P = 0.032) of metastasis
(Table 1). In contrast, TXNIP was associated with a
decreased HR (HR = 0.598; P = 0.017) (Table 1). Similar
results were obtained in the Rotterdam cohort, the Trans-
big cohort and the combined cohorts (Table 1).
Besides MFI, which captures the time between surgery
and the occurrence of a distant metastasis, disease-free
survival and overall survival were documented in the
Mainz cohort. Disease-free survival comprises metastasis
as well as local recurrence or carcinomas at the contralat-
eral breast, whereas overall survival represents the time
interval until breast-cancer-specific death. When analyz-
ing disease-free survival and overall survival (Table 2),
significant associations with TXNRD1 and TXNIP were
also obtained.
Kaplan-Meier analysis was used to visualize the associ-
ation between metastasis-free survival time and
TXNDR1 as well as TXNIP (Figure 2). The time interval
until occurrence of metastasis was shorter for patients
with TXNRD1 expression higher than the median com-
pared with patients with relatively low expression levels
(Figure 2a). In contrast, patients with high TXNIP had
longer MFI compared with patients with low TXNIP (Fig-
ure 2b).
In conclusion, the influence of TXNRD1 and TXNIP
could be confirmed in three independent cohorts of
node-negative breast cancer patients.
TXNDR1 and TXNIP in relation to known biological motives 
in breast cancer
In recent years, the genome-wide search for markers pre-
dicting prognosis in breast cancer has led to a global pic-
ture in which three coordinates representing important
biological processes have outstanding prognostic conse-
quences [31,35,36]: the proliferation metagene, consisting
of a group of genes indicating transition from slow to fast
proliferation; the B-cell and T-cell metagenes as markers
for immune cell infiltration; and estrogen-receptor-
dependent genes. In order to understand the role of
TXNRD1 and TXNIP, we determined their relation to
these three coordinates according to Freis and colleagues
[37]. TXNRD1 showed a positive correlation (R = 0.465; P
< 0.001) (Figure 3a) and TXNIP an inverse correlation (R
= -0.367; P < 0.001) with the proliferation metagene (Fig-
ure 3b). In addition, TXNRD1 showed an inverse correla-
tion with the estrogen receptor metagene (R = -0.432; P <
0.001) and a weakly positive correlation with the T-cell
metagene (R = 0.230; P < 0.001). TXNIP showed also a
weakly positive correlation with the B-cell metagene (R =
0.278; P < 0.001).
TXNRD1 is associated with ERBB2 status
To understand whether TXNRD1 and TXNIP are inde-
pendent of conventional clinical parameters, we per-
formed a multivariate Cox analysis (Table 3). For this
purpose the regression model is usually adjusted for age,
pT stage, grading, hormone (estrogen and progesterone)
receptor as well as ERBB2 status [38]. In multivariate
analysis, only TXNIP was independent of the clinical
parameters (P = 0.037; HR = 0.654) whereas TXNRD1
Table 1: Association of TXNRD1 and TXNIP RNA expression with metastasis-free survival
Prognostic factor P value HR 95% CI
Mainz cohort
(n = 200)
TXNRD1 RNA expression 0.032 1.920 1.058 to 3.486
TXNIP RNA expression 0.017 0.598 0.392 to 0.912
Rotterdam cohort
(n = 286)
TXNRD1 RNA expression 0.004 1.755 1.196 to 2.576
TXNIP RNA expression < 0.001 0.654 0.525 to 0.815
Transbig cohort
(n = 302)
TXNRD1 RNA expression 0.021 1.692 1.084 to 2.642
TXNIP RNA expression 0.013 0.639 0.448 to 0.910
Combined cohort
(n = 788)
TXNRD1 RNA expression < 0.001 1.955 1.519 to 2.518
TXNIP RNA expression < 0.001 0.642 0.554 to 0.743
Thioredoxin reductase 1 (TXNRD1) RNA expression is associated with worse metastasis-free survival in patients with node-negative breast 
cancer in the univariate Cox analysis. In contrast, thioredoxin interacting protein (TXNIP) is associated with better metastasis-free survival. 
Results obtained in the Mainz cohort could be validated in the Rotterdam cohort and in the Transbig cohort of node-negative breast cancer 
patients. In the combined cohort of 788 patients, significant associations of TXNRD1 and TXNIP with metastasis-free survival were also 
obtained. HR: hazard ratio, CI, confidence interval.
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TXNRD1 in the multivariate regression model was its
association with higher pT stage (P < 0.001), higher grad-
ing (P < 0.001), negative hormone receptor status (P <
0.001) and positive ERBB2 status (P < 0.001) (Additional
file 5).
Because of the high clinical relevance of ERBB2, its cor-
relation with TXNRD1 seemed particularly interesting
and was analyzed in detail (Figure 4a). Higher TXNRD1
expression in ERBB2-status-positive patients compared
with ERBB2-status-negative patients was observed in the
Mainz cohort. This result was confirmed in the Rotter-
dam cohort and in the Transbig cohort (Figure 4a). In
contrast to TXNRD1, the association with ERBB2 status
was much weaker for TXNIP (Figure 4b). A trend
towards lower TXNIP expression in ERBB2-status-posi-
tive patients was obtained that amounted to statistical
significance only in the combined cohort with 788
patients (Figure 4b).
In conclusion, TXNRD1 showed a positive association
and TXNIP a trend towards an inverse association with
ERBB2 status.
Other members of the thioredoxin pathway are also 
associated with prognosis in breast cancer
The findings above prompted us to investigate whether
other members of the thioredoxin pathway and down-
stream factors are also associated with prognosis of
breast cancer. For this purpose we focused on the most
prominent members of the thioredoxin pathway as sum-
marized in Figure 1. The results demonstrate that not
only expression of TXNIP and TXNRD1, the two factors
influencing the thioredoxin pathway, but also down-
stream effectors show prognostic relevance in breast can-
cer (Table 4): thioredoxin (TXN), the M2 subunit of
ribonucleotide reductase (RRM2), peroxiredoxin 2
(PRDX2), HIF-1α and VEGF were significantly associated
with worse prognosis in the combined cohort as well as in
at least one of the studied cohorts. The most convincing
association was shown by RRM2, with similar results in
all three individual cohorts. Ribonucleotide reductase
depends on activation by thioredoxin in order to reduce
ribonucleotides to deoxyribonucleotides, and therefore
supports DNA synthesis.
TXNRD1 and TXNIP depend on ERBB2 expression in MCF-7 
cells
In order to analyze whether ERBB2 influences the levels
of TXNRD1 and TXNIP expression, we used an MCF-7
cell line that allows doxycycline-dependent expression of
an oncogenic version of ERBB2 (NeuT) by the Tet-on sys-
tem [3,4]. Addition of doxycycline to the culture medium
resulted in overexpression of oncogenic ERBB2 to levels
seen in overexpressing breast carcinomas (Figure 5a).
Induced ERBB2 overexpression was accompanied by
increased phosphorylation of ERK1/2 and AKT/PKB,
illustrating that doxycycline-induced ERBB2 is functional
(Figure 5a).
As previously observed [3,4], overexpression of onco-
genic ERBB2 also induced cell cycle arrest and premature
senescence in MCF-7 cells, which is accompanied by sev-
eral phenotypical changes as can be observed in Addi-
tional file 6. ERBB2-triggered premature senescence has
been found to be mediated by the P21 protein [3], and
P21 mRNA levels were increased as early as 6 hours after
onset of NeuT expression (Additional file 7).
Interestingly, induction of ERBB2 influenced the
expression of TXNIP and TXNRD1 in a way that was
reproducible in three independent experiments: the
TXNIP transcript was immediately downregulated dur-
ing the first 24 hours after addition of doxycycline, but
recovered to initial levels at later time intervals (Figure
5b); the TXNRD1 transcript was immediately upregu-
lated after doxycycline addition and fluctuated during the
observed period, with levels remaining clearly higher
than the initial (Figure 5b); and the TXNIP and TXNRD1
proteins showed the same trend as the corresponding
transcripts, as assayed by immunoblotting. The onset of
the upregulation and downregulation appeared some-
what delayed compared with that of the transcripts (Fig-
ure 5c). In addition to this - as evidenced by analysis of
the reaction of MDA with DETBA (thiobarbituric acid
reactive substance assay) and with N-methyl-phenylin-
dole (Figure 5d), as well as by a lipid peroxidation assay
Table 2: Association of TXNRD1 and TXNIP RNA with disease-free survival and overall survival
Survival Prognostic factor P value HR 95% CI
Disease-free TXNRD1 RNA expression 0.010 2.025 1.180 to 3.476
TXNIP RNA expression 0.012 0.617 0.423 to 0.899
Overall TXNRD1 RNA expression 0.032 1.838 1.054 to 3.204
TXNIP RNA expression 0.192 0.774 0.526 to 1.137
In patients from the Mainz cohort (n = 200) of node-negative breast cancer in the univariate Cox analysis, an association of thioredoxin 
reductase 1 (TXNRD1) and thioredoxin interacting protein (TXNIP) RNA with disease-free survival and overall survival was observed. HR, hazard 
ratio; CI, confidence interval.
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Figure 2 Association of TXNRD1 and TXNIP with metastasis-free survival time. (a) High thioredoxin reductase 1 (TXNDR1) expression is associ-
ated with shorter metastasis-free survival time, (b) whereas high thioredoxin interacting protein (TXNIP) expression is associated with longer metas-
tasis-free survival time. The analysis included 788 patients with node-negative breast cancer who have not been treated by chemotherapy. Both 
TXNDR1 and TXNIP were dichotomized at the median. The log-rank test was used to assess statistical significance of the Kaplan-Meier plots.
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were clearly increased at day 14 after onset of NeuT
expression.
In conclusion, induced overexpression of ERBB2
caused alterations of TXNRD1 and TXNIP expression,
whereby TXNRD1 was upregulated and TXNIP downreg-
ulated. Both redox factors were influenced by ERBB2 in a
way that, in our patient cohorts, was associated with
worse prognosis.
Discussion
Targeting thioredoxin reductase and thioredoxin has
been suggested recently as a basis for cancer therapy,
including breast cancer [22,39,40]. The prognostic role of
TXNRD1 and TXNIP, key players of the thioredoxin sys-
tem, in node-negative breast cancer, however, has not yet
been analyzed. We therefore studied three cohorts of
patients who have not been treated by chemotherapy. In
order to understand the role of TXNRD1 and TXNIP for
the natural history of breast cancer it seemed relevant to
focus on untreated patients, because the thioredoxin sys-
tem has been reported to influence sensitivity of tumor
cells to chemotherapy [23,24,41]. We observed that high
expression of TXNRD1 was associated with worse prog-
nosis, whereas high TXNIP expression was associated
with better prognosis. These results obtained in our
Figure 3 Correlation of TXNRD1 and TXNIP with the proliferation metagene. (a) Thioredoxin reductase 1 (TXNDR1) shows a positive correlation 
with the proliferation metagene, (b) whereas thioredoxin interacting protein (TXNIP) inversely correlates with the proliferation metagene. The analysis 
includes carcinomas of 788 patients with node-negative breast cancer.
Table 3: Multivariate analysis of the association between TXNRD1 and TXNIP RNA expression with metastasis-free survival
Prognostic factor P value HR 95% CI
Age (< 50 years vs. ≥50 years) 0.511 1.176 0.725 to 1.910
pT stage (≤2 cm vs. >2 cm) < 0.001 3.526 1.866 to 6.661
Histological grade (grade III vs. grades I and II) 0.223 0.708 0.406 to 1.234
Hormone receptora, ER or PR (negative vs. positive) 0.865 0.951 0.529 to 1.707
ERBB2 status (positive vs. negative) 0.449 1.276 0.679 to 2.399
TXNRD1 RNA expression 0.162 1.445 0.862 to 2.420
TXNIP RNA expression 0.037 0.654 0.439 to 0.974
The analysis was carried out in patients with node-negative breast cancer in the univariate Cox analysis (Transbig cohort, n = 302). HR, hazard 
ratio; CI, confidence interval; TXNRD1, thioredoxin reductase 1; TXNIP, thioredoxin interacting protein. aThe hormone receptor status (HR) is 
positive as soon as either the estrogen receptor (ER) status or the progesterone receptor (PR) status is positive.
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Page 9 of 15cohort, the Mainz cohort [31], could be confirmed in two
independent, previously published cohorts - the Rotter-
dam cohort [32] and the Transbig cohort [33,34].
The inverse association of TXNRD1 and TXNIP with
MFI found in this study supports the hypothesis that the
maintenance of an active thioredoxin system is advanta-
geous to the tumor cells because it limits oxidative dam-
age and enables them to survive. Conversely, the
important ROS-independent roles of TXNIP and thiore-
doxin might as well account for the promotion of tumori-
genesis. It is noteworthy that both factors have opposite
effects on HIF-1α, in a way that thioredoxin favors its
increase and TXNIP its destabilization [42,43]. Addi-
tional associations with MFI found for thioredoxin and
downstream factors of the thioredoxin pathway, includ-
ing PRDX2, RRM2, HIF1A and VEGF, confirm the impor-
tance of the thioredoxin system in breast cancer
regardless of its ROS-related or unrelated roles.
To better understand the interrelation of TXNRD1 and
TXNIP with biologically relevant processes in breast can-
cer, we compared their expression levels with previously
published metagenes [31,35,36,38]. The most striking
correlations were observed with the proliferation meta-
gene, showing that TXNDR1 is expressed strongly in fast
proliferating tumors whereas TXNIP is expressed at low
levels, which is in accordance with published data [44-
47]. This constellation fits to the negative prognostic
influence of TXNRD1 and the favorable effect of TXNIP.
Figure 4 Association of ERBB2 status with TXNRD1 and TXNIP expression. (a) Positive ERBB2 status is associated with significantly higher levels 
of thioredoxin reductase 1 (TXNDR1) expression. A significant association was obtained in all three individual cohorts and in the combined cohort 
including 788 patients with node-negative breast cancer. (b) In contrast to TXNDR1, a trend towards lower thioredoxin interacting protein (TXNIP) 
expression was obtained in ERBB2-status-positive carcinomas. This trend, however, amounted to statistical significance only in the combined cohort.
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Page 10 of 15In addition, the estrogen receptor metagene was inversely
correlated with TXNRD1. TXNRD1 also correlated with
the T-cell metagene, which was surprising because the
latter was associated with better prognosis in our previ-
ous studies [31]. Thioredoxin is known to be secreted by
leukocytes and may exhibit cytokine-like properties in
the extracellular environment [48]. A long controversial
debate has been whether immune cell infiltration leads to
a better prognosis of breast cancer by an attack on the
tumor cells or whether secreted cytokines may cause on
adverse effect creating a microenvironment that favors
tumor cell proliferation [31].
Multivariate analysis adjusted for the conventional clin-
ical parameters serves to identify whether a new factor
adds some independent prognostic information to the
already established parameters. In the Transbig cohort,
TXNIP was independent of the established clinical
parameters, whereas TXNRD1 was not. Of course a lack
of influence in the multivariate Cox model does not
exclude biological relevance. If several genes are respon-
sible for progression of tumors from pT1 to pT4 it is likely
that tumor stage, and not one of the many genes influenc-
ing tumor stage, will be influential in the multivariate
regression model. In the case of TXNRD1, associations
Table 4: Association of other members and effectors of the thioredoxin pathway with metastasis-free survival
Prognostic factor P value HR 95% CI
Mainz cohort
(n = 200)
TXN RNA expression 0.001 3.029 1.599 to 5.738
RRM2 RNA expression 0.001 1.598 1.205 to 2.120
PRDX2 RNA expression 0.066 1.950 0.957 to 3.975
HIF1A RNA expression 0.568 0.870 0.540 to 1.403
VEGFA RNA expression 0.485 1.206 0.713 to 2.042
PTEN RNA expression 0.313 0.774 0.470 to 1.273
Rotterdam cohort
(n = 286)
TXN RNA expression 0.067 1.428 0.976 to 2.091
RRM2 RNA expression < 0.001 1.440 1.181 to 1.756
PRDX2 RNA expression 0.234 0.767 0.496 to 1.187
HIF1A RNA expression 0.003 1.545 1.160 to 2.058
VEGFA RNA expression 0.907 0.982 0.724 to 1.332
PTEN RNA expression 0.339 0.851 0.612 to 1.184
Transbig cohort
(n = 302)
TXN RNA expression 0.069 1.411 0.974 to 2.043
RRM2 RNA expression 0.003 1.354 1.107 to 1.655
PRDX2 RNA expression 0.687 1.129 0.627 to 2.033
HIF1A RNA expression 0.024 1.464 1.052 to 2.038
VEGFA RNA expression 0.045 1.393 1.007 to 1.926
PTEN RNA expression 0.197 0.802 0.573 to 1.121
Combined cohort
(n = 788)
TXN RNA expression < 0.001 1.755 1.436 to 2.145
RRM2 RNA expression < 0.001 1.469 1.298 to 1.663
PRDX2 RNA expression 0.004 1.423 1.120 to 1.807
HIF1A RNA expression < 0.001 1.440 1.184 to 1.750
VEGFA RNA expression 0.033 1.239 1.018 to 1.508
PTEN RNA expression 0.243 0.885 0.720 to 1.087
Association of TXN, RRM2, PRDX2, HIF1A, VEGF and PTEN RNA expression with metastasis-free survival in patients with node-negative breast 
cancer in the univariate Cox analysis. In the Mainz cohort, TXN and RRM2 RNA expressions are associated with worse metastasis-free survival. 
In the Rotterdam cohort, RRM2 and HIF1A are associated with metastasis-free survival. In the Transbig cohort, significant associations were 
found for RRM2, HIF1A and VEGFA. In the combined cohort of 788 patients, a significant association of all factors with metastasis-free survival, 
except PTEN, was obtained. HR, hazard ratio; CI, confidence interval.
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Figure 5 Induction of ERBB2 (NeuT) by the Tet-on system in MCF-7/NeuT cells influences TXNRD1 and TXNIP. (a) Oncogenic ERBB2 (NeuT) 
overexpression in MCF-7 cells, induced by exposure to doxycycline, triggers phosphorylation of ERK1/2 and AKT (PKB) as shown by immunoblotting. 
(b) ERBB2-mediated changes in the transcription of thioredoxin reductase 1 (TXNDR1) and thioredoxin interacting protein (TXNIP) are demonstrated 
both by Affymetrix Gene Array data and quantitative real-time PCR (qRT-PCR). The gene array graphs display the mean values (± standard deviation) 
of the Affymetrix probesets. The qRT-PCR graphs show a representative experiment of three with the mean value (± standard deviation) of a triplicate 
amplification. (c) TXNRD1 and TXNIP protein levels were analyzed by inmmunoblotting. Bands of ~55 kDa for TXNRD1 and ~50 kDa for TXNIP were 
observed. (d) An increase in accumulation of reactive oxygen species 14 days after onset of ERBB2 (NeuT) expression was shown by detection of ma-
londialdehyde by a thiobarbituric acid reactive substance (TBARS) assay and an N-methyl-2-phenylindole (NMPI) assay. The results represent the mean 
(± standard deviation) of three experiments, each measured eight times. DETBA, 1,3-diethyl-2-thiobarbituric acid.
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receptor status and ERBB2 status. We found the latter
association particularly interesting, because it might be
explained by an influence of overexpressed ERBB2 on
TXNRD1 expression levels. When we studied TXNRD1
expression in ERBB2-status-positive versus ERBB2-sta-
tus-negative carcinomas, significantly higher levels were
obtained for ERBB2-status-positive tumors in all three
individual study cohorts. Conversely, the difference in
TXNRD1 expression levels was relatively small. This
observation is not surprising, however, since an influence
of ERBB2 will probably represent only one of several fac-
tors influencing TXNRD1 expression.
Inducible expression systems with erbB2 in mice or cell
lines have contributed a lot to our understanding of
erbB2-associated mechanisms [49,50]. To understand
whether ERBB2 causes the increase in TXNRD1 expres-
sion or whether their association represents only an epi-
phenomenon of other primary events, we therefore
applied the MCF-7/NeuT cell line, which allows inducible
expression of an oncogenic version of ERBB2 (NeuT)
[3,4]. Interestingly, switching on ERBB2 caused a clear
increase in TXNRD1 mRNA and protein levels. A link
Figure 6 ERBB2-mediated altered expression of TXNRD1 and TXNIP and the association with prognosis. ERBB2 mediates upregulation of thi-
oredoxin reductase 1 (TXNDR1) expression and downregulation of thioredoxin interacting protein (TXNIP) expression, which in turn are associated with 
bad prognosis in breast cancer. TXN, thioredoxin.
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Page 13 of 15between ERBB2 and TXNRD1 expression has been estab-
lished in rat cardiomyocytes [51] where neuregulin 1β, a
ligand of the ERBB receptor tyrosine kinase, upregulated
the expression of thioredoxin and TXNRD1, among that
of other genes involved in protection against oxidative
stress, both at the mRNA and protein levels. This link
supports the possibility that the immediate early increase
in TXNRD1 mRNA levels observed after NeuT overex-
pression in our MCF-7/NeuT cell system is a direct
response to ERBB2 signaling. The high TXNRD1 levels
observed at relatively long periods (14 days) after NeuT
induction could be due to the accumulation of ROS at
this later stage. Since it is known that 4-hydroxynonenal,
one of the major products of lipid peroxidation, can
increase TXNRD1 mRNA levels via transcriptional acti-
vation of the NF-E2-related factor 2 signaling pathway
and that TXNRD1 promoter contains an antioxidant
response element [52], it is plausible that the observed
accumulation of ROS in our cells at day 14 is contributing
to the higher TXNRD1 expression at this time point.
Surprisingly, TXNIP was also influenced by NeuT but
followed a completely different kinetic, with an initial
downregulation of TXNIP transcript levels within 24
hours and a later recovery at 14 days. The immediate
decrease of TXNIP mRNA upon ERBB2 expression sug-
gests again a direct link between both factors. To our
knowledge, nothing has so far been reported concerning
a direct influence of ERBB2 signaling on TXNIP mRNA
expression. The later increase of TXNIP mRNA levels
begins concomitant with the G1 arrest of the MCF-7 cells
as they undergo senescence [3]. Although the molecular
mechanisms leading to the TXNIP biphasic behavior
remain unknown, it fits the inverse correlation of TXNIP
with the proliferation metagene observed in our study
and it agrees with the known function of the TXNIP gene
as a tumor suppressor [42].
The observed initial activation of TXNRD1 and repres-
sion of TXNIP transcription by ERBB2 signaling indepen-
dent of ROS in our MCF-7/NeuT cell model could be
interpreted as part of an ERBB2-triggered survival pro-
gram that intends to prevent later accumulation of ROS.
Further, it suggests that TXNIP and TXNRD1 are ERBB2
effectors whose multiple cellular functions contribute to
proliferation, apoptosis resistance, metabolic reprogram-
ming and, finally, to the hallmarks of ERBB2-positive
breast tumors (Figure 6).
Accumulation of ROS in senescent MCF-7/NeuT cells
(14 days) is accompanied by the recovery of TXNIP
mRNA to initial levels, which is expected to negatively
influence the ROS-scavenging activity of thioredoxin.
This could therefore partially explain increased ROS at
this stage. Interestingly, mRNA expression of thioredoxin
itself decreases slightly in MCF-7/NeuT cells at 14 days
(Additional file 9). Many other factors, however, are also
likely to contribute to the late accumulation of ROS in
senescent cells. This is under current investigation.
Conclusions
In the present article we have shown that high TXNRD1
expression and low TXNIP expression are associated with
worse prognosis in node-negative breast cancer. ERBB2
can influence expression levels of TXNRD1 and TXNIP to
shift balances in a prognostically unfavorable manner.
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